Eliem Therapeutics, Inc.

NasdaqGM:ELYM Stock Report

Mkt Cap: US$102.0m

Eliem Therapeutics Past Performance

How has Eliem Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


16.2%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: ELYM is currently unprofitable.

Growing Profit Margin: ELYM is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if ELYM's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare ELYM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ELYM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (53%).


Return on Equity

High ROE: ELYM has a negative Return on Equity (-35.75%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies